Clinical trials on Zenalux Biomedical’s experimental diagnostic system will be done at Duke University.

Durham-based Zenalux said that Duke researchers will conduct a 200-patient phase II clinical study to evaluate the company’s Zenascope C49 in assessing breast tumor margins.

The Zenascope C49 system is a uses ultraviolet-visible spectroscopic measurement hardware, proprietary software and patented algorithms to analyze tissue. The company is also studying the technology’s application in drug discovery, breast biopsy, cervical cancer and head and neck cancer detection. Zenalux said that it expects to announce additional research partnerships soon.